Phase 1 × Completed × Leukemia, Myeloid, Accelerated Phase × Clear all Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia
Phase 1 Completed
55 enrolled
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
Phase 1 Completed
R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia
Phase 1 Completed
Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation
Phase 1 Completed
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Phase 1 Completed
7 enrolled
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Phase 1 Completed
46 enrolled 11 charts
Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy
Phase 1 Completed
20 enrolled
Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Phase 1 Completed
20 enrolled
A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies
Phase 1 Completed
23 enrolled
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Phase 1 Completed
30 enrolled
Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors
Phase 1 Completed
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
Phase 1 Completed
45 enrolled
Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes
Phase 1 Completed
42 enrolled
7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes
Phase 1 Completed
30 enrolled
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
Phase 1 Completed
5 enrolled
Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia
Phase 1 Completed
24 enrolled
Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer
Phase 1 Completed
Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer
Phase 1 Completed
Radiolabeled Monoclonal Antibody Therapy and Etoposide Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Myelodysplastic Syndrome or Refractory Leukemia
Phase 1 Completed
Pyroxamide in Treating Patients With Advanced Cancer
Phase 1 Completed
Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders
Phase 1 Completed
25 enrolled
Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia
Phase 1 Completed
Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant
Phase 1 Completed
18 enrolled
Decitabine in Treating Patients With Melanoma or Other Advanced Cancer
Phase 1 Completed
Tipifarnib in Treating Patients With Advanced Hematologic Cancer
Phase 1 Completed
36 enrolled
Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate
Phase 1 Completed
48 enrolled
3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies
Phase 1 Completed
48 enrolled
Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer
Phase 1 Completed
35 enrolled
Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia
Phase 1 Completed
19 enrolled
Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia
Phase 1 Completed
5 enrolled
Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Phase 1 Completed
Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Phase 1 Completed
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
Phase 1 Completed
20 enrolled
Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Recurrent Acute Leukemia
Phase 1 Completed
Combination Chemotherapy in Treating Patients With Advanced Cancer
Phase 1 Completed
30 enrolled
Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer
Phase 1 Completed
24 enrolled
Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant
Phase 1 Completed
49 enrolled
Total-Body Irradiation, Cyclophosphamide, and Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Phase 1 Completed
Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders
Phase 1 Completed
70 enrolled
Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer
Phase 1 Completed
27 enrolled
Combination Chemotherapy Plus Infusion of White Blood Cells in Treating Patients With Hematologic Cancer
Phase 1 Completed
MS-275 in Treating Patients With Hematologic Cancer
Phase 1 Completed